New Zealand markets closed

Context Therapeutics Inc. (CNTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.3700-0.0300 (-2.14%)
As of 11:17AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 22.03M
Enterprise value -3.10M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.86
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.12

Trading information

Stock price history

Beta (5Y monthly) 2.17
52-week change 3137.52%
S&P500 52-week change 321.08%
52-week high 31.6900
52-week low 30.4700
50-day moving average 31.2379
200-day moving average 31.1230

Share statistics

Avg vol (3-month) 356.36k
Avg vol (10-day) 337.44k
Shares outstanding 515.97M
Implied shares outstanding 615.97M
Float 813.89M
% held by insiders 16.86%
% held by institutions 130.06%
Shares short (15 Apr 2024) 440.41k
Short ratio (15 Apr 2024) 40.42
Short % of float (15 Apr 2024) 40.27%
Short % of shares outstanding (15 Apr 2024) 40.25%
Shares short (prior month 15 Mar 2024) 417k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-58.01%
Return on equity (ttm)-102.79%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -25.06M
Net income avi to common (ttm)-23.96M
Diluted EPS (ttm)-1.5000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)14.45M
Total cash per share (mrq)0.9
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.83
Book value per share (mrq)0.74

Cash flow statement

Operating cash flow (ttm)-21.05M
Levered free cash flow (ttm)-12.78M